# Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

> **NCT01775618** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 73 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** BAY94-9027
- **BIOLOGICAL:** BAY94-9027
- **BIOLOGICAL:** BAY94-9027

## Key facts

- **NCT ID:** NCT01775618
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-29
- **Primary completion:** 2015-03-19
- **Final completion:** 2020-02-19
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775618, "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01775618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*